ArticleEuropean journal of medical research2025
Polyethylene glycol loxenatide reduces NETosis and immunofluorescence hyperactivation in Behçet's disease.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundNeutrophil hyperactivation, particularly through the release of neutrophil extracellular traps (NETosis), plays a crucial role in driving vascular inflammation in Behçet's disease (BD). While pyroptosis has been linked to the pathogenesis of BD, the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on neutrophil dysregulation have not been previously explored.
methodsWe investigated the effects of polyethylene glycol loxenatide (PEX168) on neutrophil activation using neutrophils isolated from BD patients, LPS-stimulated neutrophils from healthy donors, and a murine model of BD. We employed a variety of techniques, including western blotting, flow cytometry for reactive oxygen species (ROS) detection, immunohistochemistry on oral mucosa, colon, and pericardial vessels, transmission electron microscopy for cellular ultrastructure, and immunofluorescence to evaluate NETosis, pyroptosis, and inflammasome activation.
resultsPEX168 significantly and dose-dependently reduced neutrophil hyperactivation, decreasing NETosis markers (CitH3, NE, MPO) and ROS. It preserved cellular ultrastructure by mitigating mitochondrial swelling and chromatin margination. While higher concentrations inhibited the NLRP3-caspase-1-IL-1β pathway, PEX168 did not induce pyroptosis, as uncleaved GSDMD-N' remained nuclear. Low concentrations transiently enhanced IL-1β secretion, indicating biphasic immunomodulation via NF-κB.
conclusionPEX168 attenuates neutrophil hyperactivation and NETosis in Behçet's disease via ROS suppression and upstream inflammasome regulation, disrupting inflammatory signaling without provoking pyroptosis. These findings support GLP-1 RAs as a targeted treatment for neutrophil-driven autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.